169 related articles for article (PubMed ID: 38138247)
21. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
Zeng L; Zhang Y; Yang N
J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
[No Abstract] [Full Text] [Related]
22. Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report.
Chen S; Xiang T; Lu W; Hong S; Li Y; Lu Y; Zhang Q; Chen Y; Zhou S; Wang G; Zhang Z; Cai Y
Medicine (Baltimore); 2021 Feb; 100(8):e24380. PubMed ID: 33663050
[TBL] [Abstract][Full Text] [Related]
23. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
24. Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report.
Kong C; Zhou D; Wu N; Bai C
BMC Pulm Med; 2020 May; 20(1):135. PubMed ID: 32393286
[TBL] [Abstract][Full Text] [Related]
25. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.
Tamiya M; Kunimasa K; Nishino K; Matsumoto S; Kawachi H; Kuno K; Inoue T; Kuhara H; Imamura F; Goto K; Kumagai T
Invest New Drugs; 2021 Feb; 39(1):232-236. PubMed ID: 32556898
[TBL] [Abstract][Full Text] [Related]
27. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
[TBL] [Abstract][Full Text] [Related]
28. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
[TBL] [Abstract][Full Text] [Related]
29. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
Li J; Zhu L; Stebbing J; Peng L
J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
[TBL] [Abstract][Full Text] [Related]
30. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
Xu H; Liang Q; Xu X; Tan S; Wang S; Liu Y; Liu L
World J Surg Oncol; 2021 Nov; 19(1):330. PubMed ID: 34794435
[TBL] [Abstract][Full Text] [Related]
31. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
Niogret J; Coudert B; Boidot R
J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
[No Abstract] [Full Text] [Related]
32. Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Shijubou N; Sumi T; Kamada K; Sawai T; Yamada Y; Nakata H; Mori Y; Chiba H
Thorac Cancer; 2021 Mar; 12(6):989-992. PubMed ID: 33533191
[TBL] [Abstract][Full Text] [Related]
33. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
34. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
36. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
De Grève J; Moran T; Graas MP; Galdermans D; Vuylsteke P; Canon JL; Schallier D; Decoster L; Teugels E; Massey D; Chand VK; Vansteenkiste J
Lung Cancer; 2015 Apr; 88(1):63-9. PubMed ID: 25682316
[TBL] [Abstract][Full Text] [Related]
38. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
[TBL] [Abstract][Full Text] [Related]
39. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
Fang W; Huang Y; Gan J; Shao YW; Zhang L
J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
[No Abstract] [Full Text] [Related]
40. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY
Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]